<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9840">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00714285</url>
  </required_header>
  <id_info>
    <org_study_id>111295</org_study_id>
    <nct_id>NCT00714285</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate in Adults.</brief_title>
  <official_title>Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate GSK 2115160A in Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Czech Republic: State Institute for Drug Control</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and immunogenicity of GSK influenza
      vaccine candidate compared to a licensed trivalent influenza vaccine in adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Serum Haemagglutination-inhibition (HI) Antibody Titers, Against Each of the Vaccine Influenza Virus Strains.</measure>
    <time_frame>At Day 0 and Day 21</time_frame>
    <safety_issue>No</safety_issue>
    <description>Antibody titers were expressed as Geometric mean titers (GMTs).The vaccine influenza strains included A/Solomon Islands,A/Wisconsin,B/Malaysia and B/Jiangsu antigens.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroconverted for HI Antibodies Against the Vaccine Influenza Strains.</measure>
    <time_frame>At Day 21</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer less than (&lt;) 1:10 and a post-vaccination titer greater than or equal to (≥) 1:40 or a pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination titer. The vaccine influenza strains included A/Solomon Islands, A/Wisconsin, B/Malaysia and B/Jiangsu antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI Antibody Seroconversion Factors Against the Vaccine Influenza Strains</measure>
    <time_frame>Day 21</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroconversion factors were defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The Influenza vaccine strains included A/Solomon Islands, A/Wisconsin, B/Malaysia and B/Jiangsu antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Seroprotected for HI Antibodies Against the Vaccine Influenza Strains.</measure>
    <time_frame>At Days 0 and 21</time_frame>
    <safety_issue>No</safety_issue>
    <description>A seroprotected subject was defined as a subject with a serum HI titer ≥1:40 that usually is accepted as indicating protection. The Influenza vaccine strains included A/Solomon Islands, A/Wisconsin, B/Malaysia and B/Jiangsu antigens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms.</measure>
    <time_frame>During a 7 day (Days 0-6) follow-up period after vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited local symptoms assessed were pain, redness and swelling. Any was defined as occurrence of any specified solicited local symptoms reported irrespective of intensity grade. Grade 3 pain was defined as considerable pain that prevented normal activity. Grade 3 redness and swelling were defined as redness/swelling above 100 millimeters (mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Grade 3 Solicited Local Symptoms Reported by the Former GSK Rules of Grading.</measure>
    <time_frame>During a 7-day follow-up period (Days 0-6) after vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited local symptoms assessed by the former GSK rules of grading were pain, redness and swelling. Any was defined as occurrence of any specified solicited local symptoms reported irrespective of intensity grade. Grade 3 pain was defined as pain that prevented normal activity. Grade 3 redness and swelling were defined as redness/swelling above 50 millimeters (mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms.</measure>
    <time_frame>During a 7-day follow-up period (Days 0-6) after vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited general symptoms assessed were arthralgia, fatigue, headache, myalgia, nausea, shivering and fever. Any =occurrence of any specified solicited general symptoms reported irrespective of intensity grade or relationship to vaccination. Any fever = oral temperature ≥ 38.0 degrees Celsius (°C).. Grade 3 symptoms = symptoms that prevented normal activities. Grade 3 fever = oral temperature ≥39.0°C. Related = symptoms considered by the investigator to have a causal relationship to vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any ,Grade 3 and Related Solicited General Symptoms Reported by the Former GSK Rules of Grading.</measure>
    <time_frame>During a 7-day follow-up period (Days 0-6) after vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Solicited general symptoms assessed by the former GSK rules of grading were arthralgia, fatigue, headache, myalgia, nausea, shivering and fever. Any = occurrence of any specified solicited general symptoms reported irrespective of intensity grade or relationship to vaccination. Any fever = oral temperature ≥ 37.5 °C. Grade 3 symptoms = symptoms that prevented normal activities. Grade 3 fever = oral temperature above 39.0°C. . Related = symptoms considered by the investigator to have a causal relationship to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any Medically Significant Conditions (MSCs) and Auto-immune Diseases (AIDs).</measure>
    <time_frame>During the entire study period (Days 0-180)</time_frame>
    <safety_issue>No</safety_issue>
    <description>MSCs were defined as those adverse events (AEs) prompting emergency room visits, hospitalizations or physician visits and that were not routine visits for physical examination or vaccination. AIDs include a large group of diseases characterized by abnormal functioning of the immune system that causes immune system to produce antibodies against own tissues.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AE(s).</measure>
    <time_frame>During a 21 day (Days 0-20) follow-up period after vaccination-</time_frame>
    <safety_issue>No</safety_issue>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination. Grade 3 was an event that prevented normal activities and related was defined as an unsolicited AE assessed by the investigator to be causally related to the study vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)</measure>
    <time_frame>During the entire study period (Days 0-180)</time_frame>
    <safety_issue>No</safety_issue>
    <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">420</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Quadrivalent influenza vaccine GSK 2115160A Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group received 1 full dose of GSK Biologicals' quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quadrivalent influenza vaccine GSK 2115160A Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group received 1 low dose of GSK Biologicals' quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trivalent influenza vaccine GSK 2115160A Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this group received 1 low dose of GSK Biologicals' trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trivalent influenza vaccine GSK 2115160A Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this group received 1 full dose of GSK Biologicals' trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' quadrivalent influenza vaccine</intervention_name>
    <description>Single intramuscular dose on Day 0.</description>
    <arm_group_label>Quadrivalent influenza vaccine GSK 2115160A Group 1</arm_group_label>
    <arm_group_label>Quadrivalent influenza vaccine GSK 2115160A Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GSK Biologicals' trivalent influenza vaccine</intervention_name>
    <description>Single intramuscular dose on Day 0.</description>
    <arm_group_label>Trivalent influenza vaccine GSK 2115160A Group 2</arm_group_label>
    <arm_group_label>Trivalent influenza vaccine GSK 2115160A Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

          -  Subjects who the investigator believes can and will comply with the requirements of
             the protocol should be enrolled in the study.

          -  A male or female between, and including, 18 and 60 years of age at the time of the
             vaccination.

          -  Written informed consent obtained from the subject.

          -  If the subject is female, she must be of non-childbearing potential, if she is of
             childbearing potential, she must practice adequate contraception for 30 days prior to
             vaccination, have a negative pregnancy test and continue such precautions for 2
             months after completion of the vaccination series.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine(s) within 30 days preceding the administration of study vaccine, or
             planned use during the study period.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within 3 months prior to administration of the vaccine.

          -  Administration of a vaccine not foreseen in the study protocol from 30 days before
             vaccination up to 21 days post vaccination.

          -  Confirmed influenza infection within a year preceding the study start.

          -  Administration of an influenza vaccine during Northern Hemisphere season 2007-2008.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product (pharmaceutical product or device).

          -  History of hypersensitivity to a previous dose of influenza vaccine

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine(s).

          -  Acute disease at the time of enrolment.

          -  Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal
             functional abnormality, as determined by physical examination or laboratory screening
             tests.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the administration of study vaccine or planned administration during the
             study period.

          -  Pregnant or lactating female.

          -  Female planning to become pregnant or planning to discontinue contraceptive
             precautions.

          -  History of chronic alcohol consumption and/or drug abuse.

          -  Any condition which, in the opinion of the investigator, prevents the subject from
             participating in the study.

          -  History of administration of experimental/licensed vaccine.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 27, 2014</lastchanged_date>
  <firstreceived_date>July 11, 2008</firstreceived_date>
  <firstreceived_results_date>July 11, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary study</keyword>
  <keyword>immunogenicity</keyword>
  <keyword>safety</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Quadrivalent Influenza Vaccine GSK 2115160A Group 1</title>
          <description>Subjects in this group received 1 full dose of GSK Biologicals’ quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
        </group>
        <group group_id="P2">
          <title>Quadrivalent Influenza Vaccine GSK 2115160A Group 2</title>
          <description>Subjects in this group received 1 low dose of GSK Biologicals’ quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
        </group>
        <group group_id="P3">
          <title>Trivalent Influenza Vaccine GSK 2115160A Group 1</title>
          <description>Subjects in this group received 1 low dose of GSK Biologicals’ trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
        </group>
        <group group_id="P4">
          <title>Trivalent Influenza Vaccine GSK 2115160A Group 2</title>
          <description>Subjects in this group received 1 full dose of GSK Biologicals’ trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="105"/>
                <participants group_id="P3" count="105"/>
                <participants group_id="P4" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="105">Completed upto Day 180</participants>
                <participants group_id="P2" count="102">Completed upto Day 180</participants>
                <participants group_id="P3" count="105">Completed upto Day 180</participants>
                <participants group_id="P4" count="104">Completed upto Day 180</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Migrated/moved from study area</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Quadrivalent Influenza Vaccine GSK 2115160A Group 1</title>
          <description>Subjects in this group received 1 full dose of GSK Biologicals’ quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
        </group>
        <group group_id="B2">
          <title>Quadrivalent Influenza Vaccine GSK 2115160A Group 2</title>
          <description>Subjects in this group received 1 low dose of GSK Biologicals’ quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
        </group>
        <group group_id="B3">
          <title>Trivalent Influenza Vaccine GSK 2115160A Group 1</title>
          <description>Subjects in this group received 1 low dose of GSK Biologicals’ trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
        </group>
        <group group_id="B4">
          <title>Trivalent Influenza Vaccine GSK 2115160A Group 2</title>
          <description>Subjects in this group received 1 full dose of GSK Biologicals’ trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="105"/>
                <measurement group_id="B2" value="105"/>
                <measurement group_id="B3" value="105"/>
                <measurement group_id="B4" value="105"/>
                <measurement group_id="B5" value="420"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="38.5" spread="11.85"/>
                <measurement group_id="B2" value="37.6" spread="12.30"/>
                <measurement group_id="B3" value="36.6" spread="12.87"/>
                <measurement group_id="B4" value="37.4" spread="12.51"/>
                <measurement group_id="B5" value="37.5" spread="12.36"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="61"/>
                <measurement group_id="B2" value="66"/>
                <measurement group_id="B3" value="66"/>
                <measurement group_id="B4" value="58"/>
                <measurement group_id="B5" value="251"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="44"/>
                <measurement group_id="B2" value="39"/>
                <measurement group_id="B3" value="39"/>
                <measurement group_id="B4" value="47"/>
                <measurement group_id="B5" value="169"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Haemagglutination-inhibition (HI) Antibody Titers, Against Each of the Vaccine Influenza Virus Strains.</title>
        <description>Antibody titers were expressed as Geometric mean titers (GMTs).The vaccine influenza strains included A/Solomon Islands,A/Wisconsin,B/Malaysia and B/Jiangsu antigens.</description>
        <time_frame>At Day 0 and Day 21</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on According To Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Quadrivalent Influenza Vaccine GSK 2115160A Group 1</title>
            <description>Subjects in this group received 1 full dose of GSK Biologicals’ quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O2">
            <title>Quadrivalent Influenza Vaccine GSK 2115160A Group 2</title>
            <description>Subjects in this group received 1 low dose of GSK Biologicals’ quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O3">
            <title>Trivalent Influenza Vaccine GSK 2115160A Group 1</title>
            <description>Subjects in this group received 1 low dose of GSK Biologicals’ trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0.</description>
          </group>
          <group group_id="O4">
            <title>Trivalent Influenza Vaccine GSK 2115160A Group 2</title>
            <description>Subjects in this group received 1 full dose of GSK Biologicals’ trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="104"/>
                  <measurement group_id="O2" value="104"/>
                  <measurement group_id="O3" value="104"/>
                  <measurement group_id="O4" value="105"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Serum Haemagglutination-inhibition (HI) Antibody Titers, Against Each of the Vaccine Influenza Virus Strains.</title>
            <description>Antibody titers were expressed as Geometric mean titers (GMTs).The vaccine influenza strains included A/Solomon Islands,A/Wisconsin,B/Malaysia and B/Jiangsu antigens.</description>
            <units>Titer</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>A/Solomon Islands strain, Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21.4" lower_limit="16.1" upper_limit="28.4"/>
                  <measurement group_id="O2" value="22.2" lower_limit="16.6" upper_limit="29.5"/>
                  <measurement group_id="O3" value="23.3" lower_limit="17.5" upper_limit="31.0"/>
                  <measurement group_id="O4" value="18.4" lower_limit="14.3" upper_limit="23.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Solomon Islands strain, Day 21</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="130.0" lower_limit="106.1" upper_limit="159.4"/>
                  <measurement group_id="O2" value="150.6" lower_limit="118.4" upper_limit="191.5"/>
                  <measurement group_id="O3" value="160.4" lower_limit="129.1" upper_limit="199.3"/>
                  <measurement group_id="O4" value="133.8" lower_limit="105.6" upper_limit="169.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Wisconsin strain, Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29.3" lower_limit="23.0" upper_limit="37.3"/>
                  <measurement group_id="O2" value="25.7" lower_limit="19.8" upper_limit="33.3"/>
                  <measurement group_id="O3" value="30.7" lower_limit="23.7" upper_limit="39.8"/>
                  <measurement group_id="O4" value="29.0" lower_limit="22.5" upper_limit="37.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Wisconsin strain, Day 21</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="162.1" lower_limit="138.0" upper_limit="190.4"/>
                  <measurement group_id="O2" value="189.5" lower_limit="158.9" upper_limit="226.0"/>
                  <measurement group_id="O3" value="197.9" lower_limit="169.1" upper_limit="231.7"/>
                  <measurement group_id="O4" value="156.3" lower_limit="127.5" upper_limit="191.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Malaysia strain, Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32.2" lower_limit="24.8" upper_limit="41.8"/>
                  <measurement group_id="O2" value="26.6" lower_limit="20.2" upper_limit="35.0"/>
                  <measurement group_id="O3" value="23.2" lower_limit="17.7" upper_limit="30.4"/>
                  <measurement group_id="O4" value="27.2" lower_limit="20.6" upper_limit="35.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Malaysia strain, Day 21</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="192.8" lower_limit="159.6" upper_limit="232.9"/>
                  <measurement group_id="O2" value="213.0" lower_limit="174.0" upper_limit="260.9"/>
                  <measurement group_id="O3" value="187.0" lower_limit="151.9" upper_limit="230.3"/>
                  <measurement group_id="O4" value="188.5" lower_limit="150.0" upper_limit="237.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Jiangsu strain, Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19.6" lower_limit="15.6" upper_limit="24.8"/>
                  <measurement group_id="O2" value="19.5" lower_limit="15.4" upper_limit="24.5"/>
                  <measurement group_id="O3" value="23.4" lower_limit="18.3" upper_limit="29.7"/>
                  <measurement group_id="O4" value="19.2" lower_limit="15.2" upper_limit="24.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Jiangsu strain, Day 21</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="179.1" lower_limit="151.4" upper_limit="211.9"/>
                  <measurement group_id="O2" value="158.3" lower_limit="130.7" upper_limit="191.9"/>
                  <measurement group_id="O3" value="59.2" lower_limit="47.3" upper_limit="74.0"/>
                  <measurement group_id="O4" value="43.4" lower_limit="34.5" upper_limit="54.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroconverted for HI Antibodies Against the Vaccine Influenza Strains.</title>
        <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer less than (&lt;) 1:10 and a post-vaccination titer greater than or equal to (≥) 1:40 or a pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination titer. The vaccine influenza strains included A/Solomon Islands, A/Wisconsin, B/Malaysia and B/Jiangsu antigens.</description>
        <time_frame>At Day 21</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on According To Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Quadrivalent Influenza Vaccine GSK 2115160A Group 1</title>
            <description>Subjects in this group received 1 full dose of GSK Biologicals’ quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O2">
            <title>Quadrivalent Influenza Vaccine GSK 2115160A Group 2</title>
            <description>Subjects in this group received 1 low dose of GSK Biologicals’ quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O3">
            <title>Trivalent Influenza Vaccine GSK 2115160A Group 1</title>
            <description>Subjects in this group received 1 low dose of GSK Biologicals’ trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O4">
            <title>Trivalent Influenza Vaccine GSK 2115160A Group 2</title>
            <description>Subjects in this group received 1 full dose of GSK Biologicals’ trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="104"/>
                  <measurement group_id="O2" value="104"/>
                  <measurement group_id="O3" value="104"/>
                  <measurement group_id="O4" value="105"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Seroconverted for HI Antibodies Against the Vaccine Influenza Strains.</title>
            <description>A seroconverted subject was defined as a subject who had either a pre-vaccination titer less than (&lt;) 1:10 and a post-vaccination titer greater than or equal to (≥) 1:40 or a pre-vaccination titer ≥ 1:10 and at least a four-fold increase in post-vaccination titer. The vaccine influenza strains included A/Solomon Islands, A/Wisconsin, B/Malaysia and B/Jiangsu antigens.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>A/Solomon Islands strain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                  <measurement group_id="O2" value="60"/>
                  <measurement group_id="O3" value="57"/>
                  <measurement group_id="O4" value="63"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Wisconsin strain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="63"/>
                  <measurement group_id="O2" value="69"/>
                  <measurement group_id="O3" value="67"/>
                  <measurement group_id="O4" value="62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Malaysia strain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                  <measurement group_id="O2" value="68"/>
                  <measurement group_id="O3" value="59"/>
                  <measurement group_id="O4" value="62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Jiangsu strain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="79"/>
                  <measurement group_id="O2" value="82"/>
                  <measurement group_id="O3" value="28"/>
                  <measurement group_id="O4" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HI Antibody Seroconversion Factors Against the Vaccine Influenza Strains</title>
        <description>Seroconversion factors were defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The Influenza vaccine strains included A/Solomon Islands, A/Wisconsin, B/Malaysia and B/Jiangsu antigens.</description>
        <time_frame>Day 21</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on According To Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Quadrivalent Influenza Vaccine GSK 2115160A Group 1</title>
            <description>Subjects in this group received 1 full dose of GSK Biologicals’ quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O2">
            <title>Quadrivalent Influenza Vaccine GSK 2115160A Group 2</title>
            <description>Subjects in this group received 1 low dose of GSK Biologicals’ quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O3">
            <title>Trivalent Influenza Vaccine GSK 2115160A Group 1</title>
            <description>Subjects in this group received 1 low dose of GSK Biologicals’ trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O4">
            <title>Trivalent Influenza Vaccine GSK 2115160A Group 2</title>
            <description>Subjects in this group received 1 full dose of GSK Biologicals’ trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="104"/>
                  <measurement group_id="O2" value="104"/>
                  <measurement group_id="O3" value="104"/>
                  <measurement group_id="O4" value="105"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>HI Antibody Seroconversion Factors Against the Vaccine Influenza Strains</title>
            <description>Seroconversion factors were defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The Influenza vaccine strains included A/Solomon Islands, A/Wisconsin, B/Malaysia and B/Jiangsu antigens.</description>
            <units>Fold increase</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>FA/Solomon Islands strain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.1" lower_limit="4.6" upper_limit="8.0"/>
                  <measurement group_id="O2" value="6.8" lower_limit="5.0" upper_limit="9.2"/>
                  <measurement group_id="O3" value="6.9" lower_limit="5.0" upper_limit="9.4"/>
                  <measurement group_id="O4" value="7.3" lower_limit="5.3" upper_limit="9.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Wisconsin strain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.5" lower_limit="4.4" upper_limit="6.9"/>
                  <measurement group_id="O2" value="7.4" lower_limit="5.8" upper_limit="9.4"/>
                  <measurement group_id="O3" value="6.4" lower_limit="5.0" upper_limit="8.3"/>
                  <measurement group_id="O4" value="5.4" lower_limit="4.1" upper_limit="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Malaysia strain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.0" lower_limit="4.7" upper_limit="7.7"/>
                  <measurement group_id="O2" value="8.0" lower_limit="6.1" upper_limit="10.5"/>
                  <measurement group_id="O3" value="8.1" lower_limit="5.9" upper_limit="11.0"/>
                  <measurement group_id="O4" value="6.9" lower_limit="5.2" upper_limit="9.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Jiangsu strain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.1" lower_limit="7.2" upper_limit="11.5"/>
                  <measurement group_id="O2" value="8.1" lower_limit="6.6" upper_limit="10.0"/>
                  <measurement group_id="O3" value="2.5" lower_limit="2.1" upper_limit="3.0"/>
                  <measurement group_id="O4" value="2.3" lower_limit="1.9" upper_limit="2.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Seroprotected for HI Antibodies Against the Vaccine Influenza Strains.</title>
        <description>A seroprotected subject was defined as a subject with a serum HI titer ≥1:40 that usually is accepted as indicating protection. The Influenza vaccine strains included A/Solomon Islands, A/Wisconsin, B/Malaysia and B/Jiangsu antigens.</description>
        <time_frame>At Days 0 and 21</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on According To Protocol (ATP) cohort for immunogenicity which included all evaluable subjects for whom data concerning immunogenicity outcome measures were available and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Quadrivalent Influenza Vaccine GSK 2115160A Group 1</title>
            <description>Subjects in this group received 1 full dose of GSK Biologicals’ quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O2">
            <title>Quadrivalent Influenza Vaccine GSK 2115160A Group 2</title>
            <description>Subjects in this group received 1 low dose of GSK Biologicals’ quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O3">
            <title>Trivalent Influenza Vaccine GSK 2115160A Group 1</title>
            <description>Subjects in this group received 1 low dose of GSK Biologicals’ trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O4">
            <title>Trivalent Influenza Vaccine GSK 2115160A Group 2</title>
            <description>Subjects in this group received 1 full dose of GSK Biologicals’ trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="104"/>
                  <measurement group_id="O2" value="104"/>
                  <measurement group_id="O3" value="104"/>
                  <measurement group_id="O4" value="105"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Seroprotected for HI Antibodies Against the Vaccine Influenza Strains.</title>
            <description>A seroprotected subject was defined as a subject with a serum HI titer ≥1:40 that usually is accepted as indicating protection. The Influenza vaccine strains included A/Solomon Islands, A/Wisconsin, B/Malaysia and B/Jiangsu antigens.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>A/Solomon Islands strain, Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="44"/>
                  <measurement group_id="O3" value="42"/>
                  <measurement group_id="O4" value="37"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Solomon Islands strain, Day 21</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="96"/>
                  <measurement group_id="O2" value="92"/>
                  <measurement group_id="O3" value="97"/>
                  <measurement group_id="O4" value="95"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Wisconsin strain, Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                  <measurement group_id="O2" value="48"/>
                  <measurement group_id="O3" value="56"/>
                  <measurement group_id="O4" value="58"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Wisconsin strain, Day 21</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="101"/>
                  <measurement group_id="O2" value="102"/>
                  <measurement group_id="O3" value="104"/>
                  <measurement group_id="O4" value="101"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Malaysia strain, Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                  <measurement group_id="O2" value="49"/>
                  <measurement group_id="O3" value="44"/>
                  <measurement group_id="O4" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Malaysia strain, Day 21</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="101"/>
                  <measurement group_id="O2" value="101"/>
                  <measurement group_id="O3" value="100"/>
                  <measurement group_id="O4" value="98"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Jiangsu strain, Day 0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="40"/>
                  <measurement group_id="O3" value="45"/>
                  <measurement group_id="O4" value="41"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Jiangsu strain, Day 21</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="102"/>
                  <measurement group_id="O2" value="99"/>
                  <measurement group_id="O3" value="78"/>
                  <measurement group_id="O4" value="67"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms.</title>
        <description>Solicited local symptoms assessed were pain, redness and swelling. Any was defined as occurrence of any specified solicited local symptoms reported irrespective of intensity grade. Grade 3 pain was defined as considerable pain that prevented normal activity. Grade 3 redness and swelling were defined as redness/swelling above 100 millimeters (mm).</description>
        <time_frame>During a 7 day (Days 0-6) follow-up period after vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on theTotal Vaccinated cohort which included all subjects with a documented vaccine administration and symptom sheet completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Quadrivalent Influenza Vaccine GSK 2115160A Group 1</title>
            <description>Subjects in this group received 1 full dose of GSK Biologicals’ quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O2">
            <title>Quadrivalent Influenza Vaccine GSK 2115160A Group 2</title>
            <description>Subjects in this group received 1 low dose of GSK Biologicals’ quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O3">
            <title>Trivalent Influenza Vaccine GSK 2115160A Group 1</title>
            <description>Subjects in this group received 1 low dose of GSK Biologicals’ trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O4">
            <title>Trivalent Influenza Vaccine GSK 2115160A Group 2</title>
            <description>Subjects in this group received 1 full dose of GSK Biologicals’ trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="105"/>
                  <measurement group_id="O2" value="104"/>
                  <measurement group_id="O3" value="105"/>
                  <measurement group_id="O4" value="105"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms.</title>
            <description>Solicited local symptoms assessed were pain, redness and swelling. Any was defined as occurrence of any specified solicited local symptoms reported irrespective of intensity grade. Grade 3 pain was defined as considerable pain that prevented normal activity. Grade 3 redness and swelling were defined as redness/swelling above 100 millimeters (mm).</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="76"/>
                  <measurement group_id="O2" value="79"/>
                  <measurement group_id="O3" value="74"/>
                  <measurement group_id="O4" value="52"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms Reported by the Former GSK Rules of Grading.</title>
        <description>Solicited local symptoms assessed by the former GSK rules of grading were pain, redness and swelling. Any was defined as occurrence of any specified solicited local symptoms reported irrespective of intensity grade. Grade 3 pain was defined as pain that prevented normal activity. Grade 3 redness and swelling were defined as redness/swelling above 50 millimeters (mm).</description>
        <time_frame>During a 7-day follow-up period (Days 0-6) after vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated cohort which included all subjects with a documented vaccine administration and symptom sheet completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Quadrivalent Influenza Vaccine GSK 2115160A Group 1</title>
            <description>Subjects in this group received 1 full dose of GSK Biologicals’ quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O2">
            <title>Quadrivalent Influenza Vaccine GSK 2115160A Group 2</title>
            <description>Subjects in this group received 1 low dose of GSK Biologicals’ quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O3">
            <title>Trivalent Influenza Vaccine GSK 2115160A Group 1</title>
            <description>Subjects in this group received 1 low dose of GSK Biologicals’ trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O4">
            <title>Trivalent Influenza Vaccine GSK 2115160A Group 2</title>
            <description>Subjects in this group received 1 full dose of GSK Biologicals’ trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="105"/>
                  <measurement group_id="O2" value="104"/>
                  <measurement group_id="O3" value="105"/>
                  <measurement group_id="O4" value="105"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms Reported by the Former GSK Rules of Grading.</title>
            <description>Solicited local symptoms assessed by the former GSK rules of grading were pain, redness and swelling. Any was defined as occurrence of any specified solicited local symptoms reported irrespective of intensity grade. Grade 3 pain was defined as pain that prevented normal activity. Grade 3 redness and swelling were defined as redness/swelling above 50 millimeters (mm).</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="76"/>
                  <measurement group_id="O2" value="79"/>
                  <measurement group_id="O3" value="74"/>
                  <measurement group_id="O4" value="52"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="6"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Redness</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms.</title>
        <description>Solicited general symptoms assessed were arthralgia, fatigue, headache, myalgia, nausea, shivering and fever. Any =occurrence of any specified solicited general symptoms reported irrespective of intensity grade or relationship to vaccination. Any fever = oral temperature ≥ 38.0 degrees Celsius (°C).. Grade 3 symptoms = symptoms that prevented normal activities. Grade 3 fever = oral temperature ≥39.0°C. Related = symptoms considered by the investigator to have a causal relationship to vaccination</description>
        <time_frame>During a 7-day follow-up period (Days 0-6) after vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on theTotal Vaccinated cohort which included all subjects with a documented vaccine administration and symptom sheet completed</population>
        <group_list>
          <group group_id="O1">
            <title>Quadrivalent Influenza Vaccine GSK 2115160A Group 1</title>
            <description>Subjects in this group received 1 full dose of GSK Biologicals’ quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O2">
            <title>Quadrivalent Influenza Vaccine GSK 2115160A Group 2</title>
            <description>Subjects in this group received 1 low dose of GSK Biologicals’ quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O3">
            <title>Trivalent Influenza Vaccine GSK 2115160A Group 1</title>
            <description>Subjects in this group received 1 low dose of GSK Biologicals’ trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O4">
            <title>Trivalent Influenza Vaccine GSK 2115160A Group 2</title>
            <description>Subjects in this group received 1full dose of GSK Biologicals’ trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="105"/>
                  <measurement group_id="O2" value="104"/>
                  <measurement group_id="O3" value="105"/>
                  <measurement group_id="O4" value="105"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms.</title>
            <description>Solicited general symptoms assessed were arthralgia, fatigue, headache, myalgia, nausea, shivering and fever. Any =occurrence of any specified solicited general symptoms reported irrespective of intensity grade or relationship to vaccination. Any fever = oral temperature ≥ 38.0 degrees Celsius (°C).. Grade 3 symptoms = symptoms that prevented normal activities. Grade 3 fever = oral temperature ≥39.0°C. Related = symptoms considered by the investigator to have a causal relationship to vaccination</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="25"/>
                  <measurement group_id="O3" value="13"/>
                  <measurement group_id="O4" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="25"/>
                  <measurement group_id="O3" value="13"/>
                  <measurement group_id="O4" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="47"/>
                  <measurement group_id="O3" value="36"/>
                  <measurement group_id="O4" value="34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="47"/>
                  <measurement group_id="O3" value="36"/>
                  <measurement group_id="O4" value="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="36"/>
                  <measurement group_id="O3" value="28"/>
                  <measurement group_id="O4" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="26"/>
                  <measurement group_id="O4" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="40"/>
                  <measurement group_id="O3" value="33"/>
                  <measurement group_id="O4" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="40"/>
                  <measurement group_id="O3" value="33"/>
                  <measurement group_id="O4" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Nausea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Nausea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Nausea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Shivering</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="9"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Shivering</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Shivering</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="9"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any ,Grade 3 and Related Solicited General Symptoms Reported by the Former GSK Rules of Grading.</title>
        <description>Solicited general symptoms assessed by the former GSK rules of grading were arthralgia, fatigue, headache, myalgia, nausea, shivering and fever. Any = occurrence of any specified solicited general symptoms reported irrespective of intensity grade or relationship to vaccination. Any fever = oral temperature ≥ 37.5 °C. Grade 3 symptoms = symptoms that prevented normal activities. Grade 3 fever = oral temperature above 39.0°C. . Related = symptoms considered by the investigator to have a causal relationship to vaccination.</description>
        <time_frame>During a 7-day follow-up period (Days 0-6) after vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on theTotal Vaccinated cohort which included all subjects with a documented vaccine administration and symptom sheet completed</population>
        <group_list>
          <group group_id="O1">
            <title>Quadrivalent Influenza Vaccine GSK 2115160A Group 1</title>
            <description>Subjects in this group received 1 full dose of GSK Biologicals’ quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O2">
            <title>Quadrivalent Influenza Vaccine GSK 2115160A Group 2</title>
            <description>Subjects in this group received 1 low dose of GSK Biologicals’ quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O3">
            <title>Trivalent Influenza Vaccine GSK 2115160A Group 1</title>
            <description>Subjects in this group received 1 low dose of GSK Biologicals’ trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O4">
            <title>Trivalent Influenza Vaccine GSK 2115160A Group 2</title>
            <description>Subjects in this group received 1 full dose of GSK Biologicals’ trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="105"/>
                  <measurement group_id="O2" value="104"/>
                  <measurement group_id="O3" value="105"/>
                  <measurement group_id="O4" value="105"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Any ,Grade 3 and Related Solicited General Symptoms Reported by the Former GSK Rules of Grading.</title>
            <description>Solicited general symptoms assessed by the former GSK rules of grading were arthralgia, fatigue, headache, myalgia, nausea, shivering and fever. Any = occurrence of any specified solicited general symptoms reported irrespective of intensity grade or relationship to vaccination. Any fever = oral temperature ≥ 37.5 °C. Grade 3 symptoms = symptoms that prevented normal activities. Grade 3 fever = oral temperature above 39.0°C. . Related = symptoms considered by the investigator to have a causal relationship to vaccination.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any Arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="25"/>
                  <measurement group_id="O3" value="13"/>
                  <measurement group_id="O4" value="12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="25"/>
                  <measurement group_id="O3" value="13"/>
                  <measurement group_id="O4" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="47"/>
                  <measurement group_id="O3" value="36"/>
                  <measurement group_id="O4" value="34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Fatigue</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="47"/>
                  <measurement group_id="O3" value="36"/>
                  <measurement group_id="O4" value="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="36"/>
                  <measurement group_id="O3" value="28"/>
                  <measurement group_id="O4" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="26"/>
                  <measurement group_id="O4" value="23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="40"/>
                  <measurement group_id="O3" value="33"/>
                  <measurement group_id="O4" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="40"/>
                  <measurement group_id="O3" value="33"/>
                  <measurement group_id="O4" value="15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Nausea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="11"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Nausea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Nausea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="8"/>
                  <measurement group_id="O4" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Shivering</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="9"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Shivering</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="1"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Shivering</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="10"/>
                  <measurement group_id="O3" value="9"/>
                  <measurement group_id="O4" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Any Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                  <measurement group_id="O3" value="2"/>
                  <measurement group_id="O4" value="1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any Medically Significant Conditions (MSCs) and Auto-immune Diseases (AIDs).</title>
        <description>MSCs were defined as those adverse events (AEs) prompting emergency room visits, hospitalizations or physician visits and that were not routine visits for physical examination or vaccination. AIDs include a large group of diseases characterized by abnormal functioning of the immune system that causes immune system to produce antibodies against own tissues.</description>
        <time_frame>During the entire study period (Days 0-180)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated cohort which included all subjects with a documented vaccine administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Quadrivalent Influenza Vaccine GSK 2115160A Group 1</title>
            <description>Subjects in this group received 1 full dose of GSK Biologicals’ quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O2">
            <title>Quadrivalent Influenza Vaccine GSK 2115160A Group 2</title>
            <description>Subjects in this group received 1 low dose of GSK Biologicals’ quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O3">
            <title>Trivalent Influenza Vaccine GSK 2115160A Group 1</title>
            <description>Subjects in this group received 1 low dose of GSK Biologicals’ trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O4">
            <title>Trivalent Influenza Vaccine GSK 2115160A Group 2</title>
            <description>Subjects in this group received 1 full dose of GSK Biologicals’ trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="105"/>
                  <measurement group_id="O2" value="105"/>
                  <measurement group_id="O3" value="105"/>
                  <measurement group_id="O4" value="105"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any Medically Significant Conditions (MSCs) and Auto-immune Diseases (AIDs).</title>
            <description>MSCs were defined as those adverse events (AEs) prompting emergency room visits, hospitalizations or physician visits and that were not routine visits for physical examination or vaccination. AIDs include a large group of diseases characterized by abnormal functioning of the immune system that causes immune system to produce antibodies against own tissues.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>MAE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="4"/>
                  <measurement group_id="O3" value="5"/>
                  <measurement group_id="O4" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AID</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AE(s).</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination. Grade 3 was an event that prevented normal activities and related was defined as an unsolicited AE assessed by the investigator to be causally related to the study vaccination</description>
        <time_frame>During a 21 day (Days 0-20) follow-up period after vaccination-</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated cohort which included all subjects with a documented vaccine administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Quadrivalent Influenza Vaccine GSK 2115160A Group 1</title>
            <description>Subjects in this group received 1 full dose of GSK Biologicals’ quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O2">
            <title>Quadrivalent Influenza Vaccine GSK 2115160A Group 2</title>
            <description>Subjects in this group received 1 low dose of GSK Biologicals’ quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O3">
            <title>Trivalent Influenza Vaccine GSK 2115160A Group 1</title>
            <description>Subjects in this group received 1 low dose of GSK Biologicals’ trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O4">
            <title>Trivalent Influenza Vaccine GSK 2115160A Group 2</title>
            <description>Subjects in this group received 1 full dose of GSK Biologicals’ trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="105"/>
                  <measurement group_id="O2" value="105"/>
                  <measurement group_id="O3" value="105"/>
                  <measurement group_id="O4" value="105"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited AE(s).</title>
            <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination. Grade 3 was an event that prevented normal activities and related was defined as an unsolicited AE assessed by the investigator to be causally related to the study vaccination</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any unsolicited AE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="7"/>
                  <measurement group_id="O3" value="16"/>
                  <measurement group_id="O4" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Grade 3 unsolicited AE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                  <measurement group_id="O3" value="3"/>
                  <measurement group_id="O4" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related unsolicited AE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="7"/>
                  <measurement group_id="O4" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>During the entire study period (Days 0-180)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis was performed on the Total Vaccinated cohort which included all subjects with a documented vaccine administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Quadrivalent Influenza Vaccine GSK 2115160A Group 1</title>
            <description>Subjects in this group received 1 full dose of GSK Biologicals’ quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O2">
            <title>Quadrivalent Influenza Vaccine GSK 2115160A Group 2</title>
            <description>Subjects in this group received 1 low dose of GSK Biologicals’ quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O3">
            <title>Trivalent Influenza Vaccine GSK 2115160A Group 1</title>
            <description>Subjects in this group received 1 low dose of GSK Biologicals’ trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
          <group group_id="O4">
            <title>Trivalent Influenza Vaccine GSK 2115160A Group 2</title>
            <description>Subjects in this group received 1 full dose of GSK Biologicals’ trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="105"/>
                  <measurement group_id="O2" value="105"/>
                  <measurement group_id="O3" value="105"/>
                  <measurement group_id="O4" value="105"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)</title>
            <description>SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any SAE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="1.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Related SAE(s)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                  <measurement group_id="O3" value="0"/>
                  <measurement group_id="O4" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events (SAEs): During the entire study period i.e. Day 0 to Day 180 ; Solicited local and general symptoms: During Day 0- Day 6 post vaccination period.</time_frame>
      <desc>For the systematically assessed other (non-serious) adverse events, the number of participants at risk included those from Total Vaccinated cohort who had the symptom sheet completed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Quadrivalent Influenza Vaccine GSK 2115160A Group 1</title>
          <description>Subjects in this group received 1 full dose of GSK Biologicals’ quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
        </group>
        <group group_id="E2">
          <title>Quadrivalent Influenza Vaccine GSK 2115160A Group 2</title>
          <description>Subjects in this group received 1 low dose of GSK Biologicals’ quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
        </group>
        <group group_id="E3">
          <title>Trivalent Influenza Vaccine GSK 2115160A Group 1</title>
          <description>Subjects in this group received 1 low dose of GSK Biologicals’ trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
        </group>
        <group group_id="E4">
          <title>Trivalent Influenza Vaccine GSK 2115160A Group 2</title>
          <description>Subjects in this group received 1 full dose of GSK Biologicals’ trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="74" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="74" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Swellling</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="105"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
